Libedol

Diclofenac diethylamine, the active ingredient in Libedol, is a nonsteroidal anti‑inflammatory drug presented as a topical formulation for skin application. It relieves mild to moderate musculoskeletal pain and reduces inflammation in conditions such as sprains, strains, and osteoarthritis of superficial joints.

GNH USA supplies Libedol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from regulatory support, batch traceability, and on‑time delivery across multiple continents.

Libedol, a topical NSAID, is used to manage pain and inflammation in musculoskeletal conditions.

Musculoskeletal pain: provides symptomatic relief of mild to moderate pain associated with strains, sprains, and overuse injuries. Soft‑tissue inflammation: reduces local swelling, redness, and discomfort in sprains, strains, and bruises. Superficial osteoarthritis: alleviates pain and improves joint function in knee or hand osteoarthritis where the joint is near the skin surface.

Topical application of Libedol may be associated with a range of local and systemic adverse reactions.

Common Side Effects: - Skin irritation: redness, itching, or burning at the application site. - Dryness: localized dryness or peeling of the skin. - Pruritus: mild itching without rash. - Contact dermatitis: allergic skin reaction with erythema and swelling.

Serious or Rare Side Effects: - Severe allergic reaction: angioedema, urticaria, or anaphylaxis requiring immediate medical attention. - Systemic NSAID toxicity: gastrointestinal ulceration or bleeding, though rare with topical use. - Hepatotoxicity or renal impairment: signs of liver or kidney dysfunction in susceptible individuals.

When using Libedol, certain precautions should be observed to minimize risks and ensure safe use. - Assess skin integrity: avoid application on broken, infected, or inflamed skin. - Limit exposure area: do not exceed the recommended total surface area (e.g., 10% of body surface) to reduce systemic absorption. - Duration of use: limit continuous treatment to the period advised by a healthcare professional, typically not longer than 2‑4 weeks without review. - Concomitant NSAIDs: avoid using other systemic NSAIDs or topical NSAIDs concurrently to prevent additive toxicity. - Pregnancy and lactation: consult a healthcare provider before use, as safety data are limited. - Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Libedol can interact with other medicines, primarily through additive pharmacologic effects or metabolic pathways.

Major Interactions (Avoid): - Oral anticoagulants (e.g., warfarin): increased risk of bleeding. - Systemic NSAIDs or COX‑2 inhibitors: heightened risk of gastrointestinal ulceration and renal effects. - Lithium: enhanced lithium levels leading to toxicity. - Methotrexate: possible increase in methotrexate toxicity. - Corticosteroids (systemic): amplified risk of gastrointestinal complications.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: potential for reduced renal function, especially in dehydrated patients. - Diuretics: may increase risk of renal impairment when combined with NSAIDs. - Antihypertensives: possible attenuation of blood‑pressure‑lowering effect.